Get notified when SBFM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Auditor Change (new) — Company switched from Bush & Associates to M&K CPAS for 2025; new auditor identified revenue recognition as critical audit matter while prior auditor reported none.
- Asset Impairment (new) — Recorded $1.75M intangible asset impairment (46% of prior balance) after determining certain product licenses could not be commercialized.
Sunshine Biopharma cuts pipeline 66%, faces $5.3M legal claim, narrows loss despite revenue growth
Filed April 3, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 1, 2025 · ~2 min read
Key Changes
-
high
Generic drug pipeline collapsed from 64 to 22 products (66% reduction), while 75% of current portfolio depends on just three overseas suppliers—creating acute supply-chain concentration risk.
Business: Pipeline & Supplier Concentration verify on EDGAR → -
high
Former Nora Pharma president demanding $5.3M after termination; earnout payment now disputed. Separate $3.6M claim from ex-counsel resolved via favorable default judgment.
Legal Proceedings & Notes verify on EDGAR → -
high
Revenue grew 4% to $36.3M but net loss widened to $6.0M on $1.7M intangible asset write-down. Management cut liquidity runway from 24 to 18 months despite announcing $2-3M cost-reduction plan.
MD&A: Financial Performance verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade SBFM commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 3:44 PM